Related by context. All words. (Click for frequent words.) 66 IDX# 64 RDEA# 64 celgosivir 63 valopicitabine 62 CYT# 61 aflibercept 61 Marqibo 61 glufosfamide 61 PXD# 61 INCB# [001] 61 PEG Interferon lambda 61 nitazoxanide 60 TMC# [001] 60 PEG SN# 60 voreloxin 60 tolerability 60 elesclomol 60 picoplatin 60 dose cohort 60 Azixa 60 telaprevir 59 sapacitabine 59 Phase Ib 59 PS# [001] 59 talactoferrin 59 telaprevir VX 59 forodesine 59 perifosine 59 telbivudine 59 antiviral activity 58 ISIS # 58 MGCD# [002] 58 AP# [003] 58 SparVax TM 58 ProLindac 58 Phase 1b 58 pralatrexate 58 OXi# 58 Panzem R NCD 58 ALN RSV# 58 ZYBRESTAT 58 bevirimat 58 TELCYTA 58 Locteron 58 ELND# 58 belinostat 57 HGS ETR1 57 HspE7 57 ganetespib 57 XL# [003] 57 neratinib 57 Phase 1b trial 57 Perifosine 57 dacetuzumab 57 Protexia R 57 dose cohorts 57 bafetinib 57 TBC# 57 carfilzomib 57 Cloretazine R VNP#M 57 brentuximab vedotin 57 ELACYT 57 pegylated interferon 57 Phase III clinical trials 57 docetaxel 57 oral ridaforolimus 57 tolerability profile 57 HCV protease inhibitor 57 elotuzumab 57 Allovectin 7 R 57 REOLYSIN ® 57 pegloticase 57 mapatumumab 56 HGS ETR2 56 Valortim 56 pomalidomide 56 tesetaxel 56 plus ribavirin 56 Phase 2a 56 carboplatin 56 RG# [001] 56 viral kinetic 56 OncoVEX GM CSF 56 Aurexis 56 blinatumomab 56 Phase 2a trial 56 albinterferon alfa 2b 56 alvespimycin 56 TELINTRA 56 custirsen 56 alfa 2a 56 obatoclax 56 MGCD# [001] 56 R#/MEM # 56 LymphoStat B 56 danoprevir 56 daclizumab 56 favorable pharmacokinetic profile 56 tesmilifene 56 oral prodrug 56 PRX # 56 phase IIb clinical 56 zalutumumab 56 Alocrest 56 bavituximab 55 satraplatin 55 MAXY alpha 55 BCX# 55 decitabine 55 nonclinical studies 55 Albuferon 55 PSN# [002] 55 CR# vcMMAE 55 FOLOTYN 55 Amigal 55 Reolysin 55 AVE# 55 HCD# [002] 55 vicriviroc 55 IMGN# 55 Phase 1b clinical 55 axitinib 55 Alpharadin 55 NXL# 55 PEG PAL 55 docetaxel chemotherapy 55 PREZISTA r 55 ITMN 55 AVN# [001] 55 multiple ascending dose 55 EndoTAG TM -1 55 oral antiviral 55 CIMZIA TM 55 HEPLISAV 55 NEUMUNE 55 Phase Ib II 55 nucleoside 55 omacetaxine 55 Phase Ib clinical 55 MAXY G# 55 Actilon 55 Viramidine 55 MOZOBIL 55 ACTEMRA TM 55 elvucitabine 55 NGX# 55 PMX # 55 ridaforolimus 55 Phase 2b study 55 peg interferon 55 Phase 2b clinical 55 phase IIb 55 investigational drug 55 phase Ib 55 REOLYSIN R 55 rNAPc2 55 IMC A# 55 rindopepimut 55 monotherapy 54 antiviral efficacy 54 nimotuzumab 54 Genasense 54 SCH # 54 L MTP PE 54 dimebon 54 RGB # 54 Chemophase 54 Archexin 54 HGS# 54 Panzem R 54 ascending doses 54 Anthim 54 radezolid 54 Dacogen injection 54 peg IFN 54 PRT# 54 KNS # 54 potent antiviral 54 CEQ# 54 SILENOR TM 54 ISENTRESS 54 dosing cohorts 54 ixabepilone 54 Telaprevir 54 pertuzumab 54 Cethromycin 54 Protectan CBLB# 54 nab paclitaxel 54 Tarvacin TM 54 thymalfasin 54 Virulizin ® 54 velafermin 54 Zerenex 54 torezolid phosphate 54 pegylated interferon alfa 2a 54 Fibrillex TM 54 CA4P 54 Sym# 54 Glufosfamide 54 Phase III clinical 54 eniluracil 54 Allovectin 7 ® 54 dose escalation study 54 oral methylnaltrexone 54 HuMax EGFr 54 Phase Ib study 54 ASA# 54 pegylated interferon alpha 54 teduglutide 54 vosaroxin 54 TNFerade 54 Fludara 54 enzastaurin 54 CoFactor 54 bortezomib 54 JAK inhibitor 54 PLK1 SNALP 54 mcg dose 54 APD# 53 Acetavance 53 GATTEX 53 Phase Ia 53 CK # 53 GSK# [001] 53 Imprime PGG 53 Restanza 53 preclinical studies 53 Phase IIb clinical 53 Bezielle 53 pharmacodynamic 53 huC# DM4 53 Androxal TM 53 HuMax CD4 53 virologic 53 AzaSite Plus 53 vernakalant oral 53 CBLB# 53 Traficet EN 53 phase IIa 53 lesinurad 53 afatinib 53 MDV# 53 Phase IIa clinical 53 TREANDA 53 ofatumumab 53 AZD# 53 APF# 53 confirmatory Phase 3 53 INCB# [002] 53 subcutaneous formulation 53 omega interferon 53 ADVEXIN 53 ALTU 53 ponatinib 53 VEGF Trap 53 pharmacokinetic 53 docetaxel Taxotere R 53 NP2 Enkephalin 53 FTY# 53 FOLOTYN ® 53 naproxcinod 53 viral kinetics 53 DAVANAT 53 NKTR 53 Targretin 53 TOCOSOL Paclitaxel 53 preclinical 53 pradefovir 53 metaglidasen 53 dosing cohort 53 peginterferon 53 PRTX 53 Phase 2b trial 53 amrubicin 53 Asentar 53 tivozanib 53 Xcytrin 53 HCV 53 PEG interferon 53 pivotal Phase III 53 apremilast 53 trastuzumab DM1 T DM1 53 ocrelizumab 53 dose escalation 53 raxibacumab 53 telaprevir dosing 53 T DM1 53 immunomodulator 53 TYKERB 53 GLP toxicology studies 53 bicifadine 53 Hyphanox 53 Phenserine 53 lamivudine 53 antitumor activity 53 TMC# [002] 53 Tarvacin 53 cethromycin 53 mg kg dose 53 imetelstat 53 virus HCV protease inhibitor 53 Zalbin 53 elagolix 52 mg BID 52 low dose cytarabine 52 pafuramidine 52 viral suppression 52 AEG# 52 relapsed multiple myeloma 52 Peg IFN 52 Proellex TM 52 Golimumab 52 randomized Phase 52 iclaprim 52 GLPG# 52 PROMACTA 52 TYZEKA 52 velafermin belinostat 52 mg dose 52 Neuradiab 52 DASISION 52 Board DSMB 52 Antiviral Activity 52 alpha 2a 52 motesanib 52 evaluating tivozanib 52 Omacetaxine 52 tezampanel NGX# 52 cangrelor 52 integrase inhibitor 52 Tovaxin 52 AEZS 52 HER2 positive metastatic breast 52 Azedra 52 ceftaroline 52 Copegus ribavirin 52 CRx 52 dirucotide 52 JAK inhibitors 52 administered subcutaneously 52 vandetanib 52 Nanobody 52 Phase IIa trials 52 VELCADE melphalan 52 BYDUREON 52 boosted protease inhibitor 52 ribavirin 52 #ME# 52 ALKS 52 OncoVEX 52 Valortim ® 52 Atiprimod 52 #D#C# 52 LibiGel ® 52 safety tolerability pharmacokinetics 52 oral dosing 52 PDE4 inhibitor 52 zanolimumab 52 tezampanel 52 Allovectin 7 52 telaprevir dosed 52 REOLYSIN 52 Alzhemed TM 52 oral rivaroxaban 52 adefovir 52 Phase IIb 52 carboplatin paclitaxel 52 C1 INH 52 tenofovir emtricitabine 52 sustained virologic response 52 BAY #-# 52 DXL# 52 tanespimycin 52 denufosol 52 refractory gout 52 tasimelteon 52 polymerase inhibitors 52 cytarabine 52 Tarceva TM 52 SinuNase 52 COPEGUS 52 Stimuvax 52 Acute Radiation Syndrome ARS 52 GAP #B# 52 pharmacokinetics 52 romidepsin 52 Fodosine 52 seliciclib 52 ZADAXIN 52 Taxotere ® 52 GRN#L 52 Azedra TM 52 Phase #/#a trial 52 q8h 52 MLN# 52 CUDC 52 PREZISTA rtv 52 safety tolerability 52 plus dexamethasone 52 BENLYSTA ® 52 dose regimens 52 dose limiting toxicities 52 trastuzumab Herceptin R 52 otelixizumab 52 palifosfamide 52 adecatumumab 52 Ophena TM 52 maximally tolerated dose 52 faropenem 52 VEGF Trap Eye 52 RSD# 52 Androxal 52 APTIVUS r 52 HGS ETR1 mapatumumab 52 investigational hepatitis C 52 phase IIa clinical 51 Onrigin TM 51 immunogenicity 51 TRISENOX 51 paclitaxel Taxol ® 51 Vidaza 51 VQD 51 bendamustine 51 LibiGel Phase III 51 plus gemcitabine 51 nucleoside analogue 51 Tolerability 51 limiting toxicity 51 pharmacokinetics pharmacodynamics 51 HRPC 51 panitumumab 51 Xeloda ® 51 safety tolerability pharmacokinetic 51 ASONEP 51 pharmacodynamic profile 51 vilazodone 51 Phase IIa clinical trials 51 iSONEP 51 BiovaxID 51 Carfilzomib 51 Pegasys plus Copegus 51 metastatic hormone refractory 51 ANAVEX #-# [003] 51 Plicera 51 peginesatide 51 Phase 2b 51 posaconazole 51 Triolex 51 eltrombopag 51 oritavancin 51 MAGE A3 ASCI 51 Pegasys ® 51 lintuzumab 51 Pegasys peginterferon alfa 2a 51 Telbivudine 51 Aptivus ® 51 RSD# oral 51 metastatic castration resistant 51 gemcitabine 51 Vilazodone 51 MYDICAR ® 51 taribavirin 51 Cotara 51 cilengitide 51 elacytarabine 51 Thiovir 51 ABC/3TC 51 hematologic malignancies 51 SVR# 51 registrational 51 XmAb# 51 ENMD 51 active comparator 51 pharmacokinetic properties 51 BARACLUDE R 51 Bicifadine 51 AEOL # 51 novel VDA molecule 51 Phase IIa trial 51 indiplon capsules 51 pharmacodynamic properties 51 LEXIVA r 51 MEK inhibitor RDEA# 51 Bortezomib 51 Bronchitol 51 Taxotere R 51 CBLC# 51 investigational monoclonal antibody 51 LEVADEX 51 S/GSK# 51 unique alkylating agent 51 farletuzumab 51 Satraplatin 51 MAP# 51 FluCide 51 efficacy endpoints 51 CD NP 51 dacetuzumab SGN 51 bortezomib Velcade R 51 Phase IIb trials 51 RhuDex ® 51 Sulonex 51 anti leukemic 51 alvimopan 51 VELCADE 51 ORENCIA ® 51 TRO# 51 CCR5 antagonist 51 arzoxifene 51 AEGR 51 ara C 51 Veronate 51 Xanafide 51 paliperidone ER 51 Cinryze 51 HuLuc# 51 Daclizumab 51 RE SURGE 51 Voreloxin 51 Romidepsin 51 mcg kg 51 Vectibix 51 JANUVIA 51 mg/m2 51 Hsp# inhibitor 51 Anturol 51 pivotal Phase 51 CRLX# 51 peginterferon alfa 2a 51 HQK 51 IMP# 51 dose escalation trial 51 dacarbazine 51 CRMD# 51 vinorelbine 51 ongoing Phase 1b 51 pegylated interferon alfa 2b 51 pixantrone 51 AeroLEF TM 51 Corlux 51 Insegia 51 eculizumab 51 HuMax CD# 51 comparator arm 51 veltuzumab 51 Capesaris 51 Phase #b/#a 50 investigational compound 50 LEP ETU 50 ambrisentan 50 Æterna Zentaris 50 PEG Intron 50 ascending dose 50 blinded randomized placebo controlled 50 CLORETAZINE TM VNP#M 50 mGluR5 NAM 50 oral FTY# 50 Phase 1a 50 LY# [003] 50 mocetinostat MGCD# 50 nanoviricide drug 50 omecamtiv mecarbil 50 Empatic 50 tolerability profiles 50 NEUVENGE 50 treatment naïve genotype 50 abiraterone acetate 50 efficacy tolerability 50 GED aPC 50 CORLUX 50 rALLy trial 50 selective androgen receptor modulator 50 CDP# 50 IND enabling 50 Valortim R 50 APTIVUS 50 evaluable patients 50 plus prednisone 50 Phase IIIb clinical 50 YONDELIS 50 Prochymal 50 AQ4N 50 vidofludimus 50 lorvotuzumab mertansine 50 ApoB SNALP 50 Belinostat 50 pharmacokinetic profile 50 Virulizin R 50 dosing regimens 50 sunitinib malate 50 tolerated dose MTD 50 ORENCIA R 50 mipomersen 50 phase 2a 50 TRIOLEX 50 non nucleoside HCV 50 BiTE antibody 50 ulimorelin 50 Amrubicin 50 ONTAK 50 antiviral potency 50 BENLYSTA 50 treatment naive genotype 50 transcriptase inhibitor NNRTI 50 GAMMAGARD 50 Telintra 50 Ribavirin 50 Darusentan 50 XL# XL# XL# XL# 50 Sapacitabine 50 EFAPROXYN 50 subcutaneously administered 50 Apoptone 50 Proxinium TM 50 ICA # 50 temozolomide 50 Synavive 50 Phase IIa 50 SinuNase TM 50 UVIDEM 50 placebo controlled Phase 50 MEK Inhibitor 50 lomitapide 50 KRN# 50 forodesine HCl 50 exenatide once 50 adalimumab 50 refractory chronic lymphocytic 50 Civacir 50 oral deforolimus 50 darunavir ritonavir 50 #mg/m# [001] 50 Cloretazine 50 Ocrelizumab 50 IRX 2 50 randomized Phase 2b 50 capecitabine Xeloda R 50 phenoxodiol 50 doripenem 50 NEUGENE antisense 50 Trastuzumab 50 ILLUMINATE 50 entecavir 50 Laquinimod 50 Cloretazine ® 50 PF # [001] 50 maribavir 50 MERLIN TIMI 50 PEG Interferon alfa 50 REVLIMID lenalidomide 50 non nucleoside polymerase 50 Poly ICR 50 Trofex TM 50 secondary efficacy endpoints 50 Shigamabs ® 50 ILUVIEN ® 50 ALN PCS 50 ISTODAX 50 apricitabine 50 pegylated interferons 50 Phenoptin 50 peginterferon alfa 50 bazedoxifene 50 ribavirin RBV 50 raltegravir 50 Vacc 4x 50 erlotinib Tarceva ® 50 bevacizumab Avastin ® 50 Mipomersen 50 DR Cysteamine 50 methylnaltrexone 50 orally administered inhibitor 50 Ramoplanin 50 rFIXFc 50 Symadex 50 REBETOL 50 Nexavar ® 50 Ostarine 50 Exelixis compounds 50 resminostat 50 protease inhibitor 50 refractory Hodgkin lymphoma 50 Fx #A 50 uric acid lowering 50 Afatinib 50 PROVENGE 50 TKM ApoB 50 lenalidomide 50 TCAD therapy 50 mertansine 50 Vicriviroc 50 registrational studies 50 anti EGFR antibody 50 oral formulation 50 oral bioavailability 50 FavId 50 Phase IIb trial 50 ritonavir boosted danoprevir 50 Phase IIb clinical trials 50 brivaracetam 50 Reverset 50 indibulin 50 ORMD 50 NVA# 50 Forodesine HCl 50 virus HCV infection 50 ONCONASE 50 Menerba 50 Pegasys R 50 fidaxomicin 50 GVAX 50 sorafenib tablets 50 dextromethorphan quinidine 50 QLT# 50 DU #b 50 DexaSite 50 PEGASYS ® 50 davunetide intranasal AL 50 IIa trial 50 Nasulin 50 ipilimumab 50 hematological malignancies 50 diabetic neuropathic pain 50 ostarine 50 clinical trial 50 TLK# 50 metastatic castrate resistant 50 vivo efficacy 50 LymphoStat B TM 50 UPLYSO 50 XL# XL# XL# 50 targeting CD# 50 Serdaxin 50 PEG INTRON 50 fostamatinib 50 Tekamlo 50 hepatitis C protease inhibitor 50 anticancer activity 50 DEB# 50 ARRY 50 velaglucerase alfa 50 GFT# 50 protease inhibitor PI 50 pharmacokinetics PK 50 urate lowering 50 refractory multiple myeloma 50 hematological cancers 50 chronic HCV infection 50 epothilone 50 TRISENOX ® 50 polymerase inhibitor 50 AGILECT R 50 investigational protease inhibitor 50 demonstrated antitumor activity 50 Pimavanserin 50 CD# CEA 50 REYATAZ R 50 aflibercept VEGF Trap 50 crizotinib PF # 50 Ampligen R 50 null responder HCV 50 dasatinib 50 Phase III trials 50 lenalidomide Revlimid R 50 liposomal formulation 49 ramelteon 49 novel anticancer 49 CCX# 49 Debio 49 THALOMID 49 Annamycin 49 R# #mg BID 49 Jevtana 49 intermittent dosing 49 peginterferon alfa 2b 49 GLYX 49 IMiDs 49 lapatinib Tykerb 49 brentuximab vedotin SGN 49 EZN 49 orBec 49 pharmacokinetic studies 49 mRCC 49 cell lymphoma CTCL 49 interferon ribavirin 49 TRAIL receptor antibodies 49 IMA# 49 FOLFIRI 49 FOLPI regimen 49 Chrysalin 49 lintuzumab SGN 49 PROSTVAC TM 49 RLY# 49 ferumoxytol 49 goserelin 49 registrational trial 49 Trizytek 49 DOXIL 49 Phase 1a clinical 49 ZK EPO 49 temsirolimus 49 orally bioavailable 49 MVA BN R 49 NEUGENE 49 dose regimen 49 refractory AML 49 MEK inhibitors 49 APOPTONE 49 talabostat 49 SERMs 49 atazanavir ritonavir 49 Tyrima 49 ONGLYZA ™ 49 Cimzia ® 49 antisense drug 49 μg dose 49 NLX P# 49 q#h 49 RAD# [003] 49 QNEXA 49 #mg/m# [002] 49 Pazopanib 49 pharmacokinetic PK 49 oxymorphone ER 49 Elotuzumab 49 ABRAXANE 49 peginterferon alfa 2a #KD 49 fosbretabulin 49 Lenocta 49 bifeprunox 49 dosage regimens 49 azacitidine 49 Neulasta ® 49 OHR/AVR# 49 boceprevir 49 ARIKACE 49 sorafenib Nexavar R 49 CIMZIA ™ 49 deforolimus 49 SNT MC# 49 Hollis Eden 49 gemcitabine Gemzar 49 Ceflatonin 49 generation purine nucleoside 49 tipranavir r 49 cetuximab Erbitux ® 49 AZT zidovudine Retrovir 49 Shigamabs R 49 Revimmune 49 systemically administered 49 ZEGERID Capsules 49 clofarabine 49 maraviroc 49 ZYBRESTAT fosbretabulin 49 hormone refractory prostate cancer 49 Phase 2a clinical 49 sunitinib 49 PegIntron 49 Neurodex 49 ritonavir boosted 49 rHuPH# 49 Altastaph 49 SAR# [004] 49 EOquin 49 clevidipine 49 Riquent 49 PDX pralatrexate 49 antiviral 49 preclinical toxicology 49 Plenaxis TM 49 XGEVA 49 NDA submission 49 DermaVir Patch 49 CANCIDAS 49 alkylating agent 49 PEGASYS 49 preclinical pharmacokinetic 49 relapsed MM 49 MBP# [001] 49 Onrigin 49 HCV SPRINT 49 hepatitis C virus HCV 49 PI3K/Akt pathway inhibitor 49 sorafenib Nexavar 49 Elacytarabine 49 topotecan 49 Herceptin trastuzumab 49 tramiprosate Alzhemed TM 49 Arikace 49 gemcitabine cisplatin 49 Ixempra 49 Defibrotide 49 nilotinib 49 bosutinib 49 Vitaxin 49 clodronate 49 YERVOY 49 LAF# 49 ThermoDox R 49 Triapine R 49 Elvitegravir 49 carcinogenicity study 49 delafloxacin 49 anticancer 49 interferon alfa 2a 49 OvaRex ® MAb 49 Viral Immunotherapy platform 49 pharmacokinetic PK study 49 Diamyd ® 49 atacicept 49 PREZISTA ritonavir 49 AACR NCI EORTC 49 anti TNF alpha 49 CYC# 49 VIR# 49 BMS # 49 ONCONASE R 49 BARACLUDE ® 49 capecitabine 49 virologic failure 49 standard chemotherapy regimen 49 GALNS 49 SPRYCEL ® 49 ribavirin therapy 49 CCR9 antagonist 49 CORLUX CORT # 49 PEGPH# 49 INGN 49 rituximab 49 Seliciclib 49 Hsp# inhibitors 49 gemcitabine Gemzar ® 49 CORT # 49 AZILECT R 49 HDAC Inhibitor 49 bone metastases 49 etravirine 49 entinostat 49 rhC1INH 49 Gemzar ® 49 NNRTI 49 mitoxantrone 49 TACI Ig 49 taxane 49 #mg QD [001] 49 baminercept 49 omacetaxine mepesuccinate 49 Onconase 49 SUCCEED trial 49 lapatinib 49 CD# monoclonal antibody 49 non nucleoside reverse 49 oral JAK#/JAK# inhibitor 49 metastatic HRPC 49 Aflibercept 49 ritonavir boosted protease inhibitor 49 investigational compounds 49 dexpramipexole 49 placebo controlled clinical trials 49 relapsed refractory multiple myeloma 49 Vectibix monotherapy 49 NOX E# 49 2 methoxyestradiol 49 estramustine 49 oral Azacitidine 49 prGCD 49 rapid virologic response 49 tipranavir 49 Advexin 49 Dapagliflozin 49 mg/m2/day 49 Quinamed 49 GRNVAC1 49 plasma uric acid 49 8mg/kg 49 ATL# [001] 49 PSMA ADC 49 XYOTAX 49 alfimeprase 49 ALN TTR# 49 NB S# 49 PROSTVAC VF 49 isavuconazole 49 ALVESCO 49 TRIZIVIR 49 idarubicin 49 Telcyta 49 BZL# 49 XL# XL# 49 Qnexa 49 vemurafenib 49 MYCAMINE 49 octreotide acetate 49 Phase IIB 49 ATryn R 49 Zenvia 49 PREOS 49 VNP#M 49 safinamide